v3.26.3
Fair Value Measurements and Marketable Equity Securities - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2026
Jun. 30, 2026
Aug. 31, 2024
Sep. 30, 2026
Aug. 31, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Aug. 30, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Carrying value of measurement alternative investments       $ 25,500,000     $ 25,500,000   $ 8,000,000    
Cumulative upward and downward adjustments from observable price       0     0        
Impairment loss       $ 0   $ 0 0 $ 0      
Aggregate proceeds from sale of marketable equity securities             $ 0 $ 8,316,000      
Pathos Series D Preferred Stock [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Class of warrants       23,456,790     23,456,790        
Data license fees received from counterparty $ 8,800,000 $ 8,800,000     $ 17,500,000            
Investment In Recursion Pharmaceuticals Class A Common Stock [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Investment in equity securities at fair value sold number of shares       0     0 737,466      
Weighted average price per share of investment sold               $ 11.28      
Aggregate proceeds from sale of marketable equity securities               $ 8,300,000      
Outstanding common stock percentage             20.00%        
Pathos AI [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Warrant to purchase shares of common stock value       $ 0     $ 0        
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Class Of Warrant Share Issued       9,218,800     9,218,800       9,218,800
Common stock purchase price     $ 18,400,000                
Purchase of additional shares of common stock     3,500,000                
Purchase of additional shares of common stock value     $ 17,700,000                
Outstanding common stock percentage     20.00%                
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Class of Warrant or Right, Exercise Price of Warrants or Rights                   $ 1.5  
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Class of Warrant or Right, Exercise Price of Warrants or Rights                   $ 2.5  
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312024 [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Class Of Warrant Excisable At Cash       4,609,400     4,609,400        
Maximum [Member] | Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December312025 [Member]                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Class Of Warrant Excisable At Cash                   4,609,400